OOIR: Observatory of International Research

Papers

(The H4-Index of ACS Infectious Diseases is 37. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease	218
Endogenous Deficiency of Glutathione as the Most Likely Cause of Serious Manifestations and Death in COVID-19 Patients	185
Proteolytic Activation of SARS-CoV-2 Spike at the S1/S2 Boundary: Potential Role of Proteases beyond Furin	122
Anti-SARS-CoV-2 Potential of Artemisinins In Vitro	113
Current and Perspective Diagnostic Techniques for COVID-19	112
Recent Innovations in Bacterial Infection Detection and Treatment	108
Are Quaternary Ammonium Compounds, the Workhorse Disinfectants, Effective against Severe Acute Respiratory Syndrome-Coronavirus-2?	91
Comparative Analysis of Primer–Probe Sets for RT-qPCR of COVID-19 Causative Virus (SARS-CoV-2)	90
Comparative Multiplexed Interactomics of SARS-CoV-2 and Homologous Coronavirus Nonstructural Proteins Identifies Unique and Shared Host-Cell Dependencies	78
Zoliflodacin: An Oral Spiropyrimidinetrione Antibiotic for the Treatment of Neisseria gonorrheae, Including Multi-Drug-Resistant Isolates	74
Synthetic Antimicrobial Polymers in Combination Therapy: Tackling Antibiotic Resistance	72
Small-Molecule Inhibitors of the Coronavirus Spike: ACE2 Protein–Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2	71
Electrochemical Diagnostics for Bacterial Infectious Diseases	68
Challenges for Targeting SARS-CoV-2 Proteases as a Therapeutic Strategy for COVID-19	68
Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses	68
Human Cathelicidin Inhibits SARS-CoV-2 Infection: Killing Two Birds with One Stone	64
Prospecting Human Milk Oligosaccharides as a Defense Against Viral Infections	58
The SARS-CoV-2 Cytopathic Effect Is Blocked by Lysosome Alkalizing Small Molecules	57
Effects of Antibiotic Treatment on Gut Microbiota and How to Overcome Its Negative Impacts on Human Health	57
Clinical and Laboratory Diagnosis of SARS-CoV-2, the Virus Causing COVID-19	55
The Structure-Based Design of SARS-CoV-2 nsp14 Methyltransferase Ligands Yields Nanomolar Inhibitors	54
Exogenous Nitric Oxide Improves Antibiotic Susceptibility in Resistant Bacteria	51
Recognition of Divergent Viral Substrates by the SARS-CoV-2 Main Protease	51
Emerging Vaccine-Breakthrough SARS-CoV-2 Variants	47
Two Years into the COVID-19 Pandemic: Lessons Learned	46

Reproducible Breath Metabolite Changes in Children with SARS-CoV-2 Infection	46
Current Perspective of Antiviral Strategies against COVID-19	45
The Antibacterial Research and Development Pipeline Needs Urgent Solutions	42
Codelivery of Sustainable Antimicrobial Agents and Platelet-Derived Growth Factor via Biodegradable Nanofibers for Repair of Diabetic Infectious Wounds	41
Structure–Activity Relationship Studies of Acetazolamide-Based Carbonic Anhydrase Inhibitors with Activity against Neisseria gonorrhoeae	40
Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19	39
Prioritization of Molecular Targets for Antimalarial Drug Discovery	39
Plasmodium Kinases as Potential Drug Targets for Malaria: Challenges and Opportunities	39
Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2?	38
Mucin-Degrading Microbes Release Monosaccharides That Chemoattract Clostridioides difficile and Facilitate Colonization of the Human Intestinal Mucus Layer	38
Kanamycin Uptake into Escherichia coli Is Facilitated by OmpF and OmpC Porin Channels Located in the Outer Membrane	38
Self-Assembly of Antimicrobial Peptoids Impacts Their Biological Effects on ESKAPE Bacterial Pathogens	37